Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9815905rdf:typepubmed:Citationlld:pubmed
pubmed-article:9815905lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:9815905lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:9815905lifeskim:mentionsumls-concept:C1519429lld:lifeskim
pubmed-article:9815905lifeskim:mentionsumls-concept:C0021757lld:lifeskim
pubmed-article:9815905lifeskim:mentionsumls-concept:C0280100lld:lifeskim
pubmed-article:9815905lifeskim:mentionsumls-concept:C1527200lld:lifeskim
pubmed-article:9815905lifeskim:mentionsumls-concept:C0920321lld:lifeskim
pubmed-article:9815905lifeskim:mentionsumls-concept:C0280617lld:lifeskim
pubmed-article:9815905lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:9815905pubmed:issue10lld:pubmed
pubmed-article:9815905pubmed:dateCreated1999-2-9lld:pubmed
pubmed-article:9815905pubmed:abstractTextRecombinant human interleukin 3 (rhIL-3, expressed in Escherichia coli) is a hematopoietic growth factor with protean biological effects on bone marrow in animal models, including enhanced granulocyte and platelet production and the capacity to ameliorate chemotherapy-induced bone marrow toxicity. We, therefore, undertook a Phase I trial in patients with advanced solid tumors and normal bone marrow function. Cohorts of four to six patients each received daily s.c. doses of rhIL-3 (SDZ-ILE-964; Sandoz) at dose levels of 1. 0, 2.5, 5.0, and 10.0 microgram/kg according to the following schedule: cycle 1, rhIL-3 days 1-14; cycle 2, carboplatin (350 mg/m2) on day 1 and etoposide (100 mg/m2) on days 1-3; and cycle 3, carboplatin (350 mg/m2) on day 1, etoposide (100 mg/m2) on days 1-3, and rhIL-3 on days 4-17. Each cycle was a total of 28 days. An analysis of 20 patients entered into all four escalating dose levels revealed that, during cycle 1, absolute neutrophil count (ANC) increased from a median baseline of 6,643/mm3 to a median of 12,692/mm3, and platelets increased from a median baseline of 314,000/mm3 to a median of 465,000/mm3. When cycle 2 was compared with cycle 3, the median ANC nadir increased from 192/mm3 to 988/mm3, and the mean ANC nadir increased from 458/mm3 to 1,297/mm3. Median platelet count nadirs increased from 29,000/mm3 to 84,000/mm3, and the mean nadir platelet counts increased from 72,000/mm3 to 129,000/mm3. Total days on which platelets were <50,000/mm3 was 52 for cycle 2 and 19 for cycle 3. The maximum tolerated dose of rhIL-3 was 5.0 microgram/kg/day; dose-limiting toxicities included fatigue, chills, fever, and headache. These data suggest a clear but variable biological activity observed with IL-3, as measured by the reduction in the depth and duration of thrombocytopenia and/or neutropenia when cycle 2 was compared with cycle 3. rhIL-3 is a promising cytokine that may help to ameliorate the bone marrow toxicity observed with the use of chemotherapeutic agents.lld:pubmed
pubmed-article:9815905pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9815905pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9815905pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9815905pubmed:languageenglld:pubmed
pubmed-article:9815905pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9815905pubmed:citationSubsetIMlld:pubmed
pubmed-article:9815905pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9815905pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9815905pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9815905pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9815905pubmed:statusMEDLINElld:pubmed
pubmed-article:9815905pubmed:monthOctlld:pubmed
pubmed-article:9815905pubmed:issn1078-0432lld:pubmed
pubmed-article:9815905pubmed:authorpubmed-author:LevittDDlld:pubmed
pubmed-article:9815905pubmed:authorpubmed-author:RinehartJJlld:pubmed
pubmed-article:9815905pubmed:authorpubmed-author:HershEElld:pubmed
pubmed-article:9815905pubmed:authorpubmed-author:MargolinK AKAlld:pubmed
pubmed-article:9815905pubmed:authorpubmed-author:TriozziPPlld:pubmed
pubmed-article:9815905pubmed:authorpubmed-author:CampionMMlld:pubmed
pubmed-article:9815905pubmed:authorpubmed-author:RestaDDlld:pubmed
pubmed-article:9815905pubmed:issnTypePrintlld:pubmed
pubmed-article:9815905pubmed:volume1lld:pubmed
pubmed-article:9815905pubmed:ownerNLMlld:pubmed
pubmed-article:9815905pubmed:authorsCompleteYlld:pubmed
pubmed-article:9815905pubmed:pagination1139-44lld:pubmed
pubmed-article:9815905pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:9815905pubmed:meshHeadingpubmed-meshheading:9815905-...lld:pubmed
pubmed-article:9815905pubmed:meshHeadingpubmed-meshheading:9815905-...lld:pubmed
pubmed-article:9815905pubmed:meshHeadingpubmed-meshheading:9815905-...lld:pubmed
pubmed-article:9815905pubmed:meshHeadingpubmed-meshheading:9815905-...lld:pubmed
pubmed-article:9815905pubmed:meshHeadingpubmed-meshheading:9815905-...lld:pubmed
pubmed-article:9815905pubmed:meshHeadingpubmed-meshheading:9815905-...lld:pubmed
pubmed-article:9815905pubmed:meshHeadingpubmed-meshheading:9815905-...lld:pubmed
pubmed-article:9815905pubmed:meshHeadingpubmed-meshheading:9815905-...lld:pubmed
pubmed-article:9815905pubmed:meshHeadingpubmed-meshheading:9815905-...lld:pubmed
pubmed-article:9815905pubmed:meshHeadingpubmed-meshheading:9815905-...lld:pubmed
pubmed-article:9815905pubmed:meshHeadingpubmed-meshheading:9815905-...lld:pubmed
pubmed-article:9815905pubmed:meshHeadingpubmed-meshheading:9815905-...lld:pubmed
pubmed-article:9815905pubmed:meshHeadingpubmed-meshheading:9815905-...lld:pubmed
pubmed-article:9815905pubmed:meshHeadingpubmed-meshheading:9815905-...lld:pubmed
pubmed-article:9815905pubmed:meshHeadingpubmed-meshheading:9815905-...lld:pubmed
pubmed-article:9815905pubmed:meshHeadingpubmed-meshheading:9815905-...lld:pubmed
pubmed-article:9815905pubmed:meshHeadingpubmed-meshheading:9815905-...lld:pubmed
pubmed-article:9815905pubmed:meshHeadingpubmed-meshheading:9815905-...lld:pubmed
pubmed-article:9815905pubmed:year1995lld:pubmed
pubmed-article:9815905pubmed:articleTitlePhase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors: a southwest oncology group study.lld:pubmed
pubmed-article:9815905pubmed:affiliationScott & White Clinic and Memorial Hospital, Temple, Texas 76508, USA.lld:pubmed
pubmed-article:9815905pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9815905pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:9815905pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:9815905pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:9815905pubmed:publicationTypeClinical Trial, Phase Illd:pubmed